Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina that ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin ... Eli Lilly CEO says Mounjaro maker may consider other ... Nexus Pharmaceuticals sets month for $100M plant ...

Lilly’s tremendous success with Mounjaro and Zepbound made it the biggest drugmaker in the world, with a market cap of more than $800 million. Mounjaro and Zepbound’s big sales miss ...

Drugmaker Eli Lilly plans to build four new manufacturing plants in the U.S., a $27 billion investment that the company expects will create 3,000 high-skilled jobs and employ 10,000 construction ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States ...

Eli Lilly has unveiled plans to invest $27 billion in the construction of four new manufacturing plants in the United States. Getty Images. The new sites will be announced later this year and are ...

Lilly markets tirzepatide as Zepbound for obesity and Mounjaro for type II diabetes. Per management, this is Lilly’s single largest manufacturing investment outside its home state of Indianapolis.

Eli Lilly is investing heavily in expanding its highly regulated manufacturing plants, which haven’t been able to keep up with demand for its most sought-after drugs, he explained.